XR-17 encapsulates individual APIs in a layer of micelles, making the API and micelle formulation water soluble and therefore usable in water based intravenous injections.

Vivesto’s toxicological and clinical studies suggest XR-17’s beneficial properties such as:

  • Improved delivery of intravenously administered drugs, intended to avoid mandatory use of corticosteroid before intravenous administration
  • Shorter intravenous infusion times than with some solvent-based versions of the drugs, making treatment more convenient for patients and healthcare providers
  • Favorable API to solvent ratio, intended to keep solvent portion of the drug low while maximizing the API delivery
  • Free of alcohol as well as animal and human proteins